Research, discovery, and translation to practice are at the core of the mission for the George Washington University School of Medicine and Health Sciences. By accelerating research excellence, enhancing innovation, and advancing translation, our goal is to make discoveries and improve clinical care.
The scientific workforce, composed of highly educated researchers and scientists-in training, clinician investigators, as well as skilled technical support staff, project managers, and core team members, together contribute to research discovery. Training the next generation of biomedical scientists is a key goal.
Funding and support, obtained from federal and non-federal grants and contracts, private industry investment, and philanthropy, is essential to sustain our research programs. SMHS provides funding opportunities and strategies to gain support.
Moncef Slaoui, PhD, MBA, chief adviser for the COVID-19 vaccine development initiative Operation Warp Speed, visited GW on Oct. 21 to raise awareness for the national vaccine development efforts, encourage greater participation in the clinical trials and recognize GW for exceeding its enrollment goals for its vaccine trial.
A recent study by GW physicians on the severity of acute respiratory viral adverse events related to antirheumatic disease therapies found that some therapies may be associated with increased respiratory viral events while others don’t show increased frequency.
While COVID-19 infected patients should be treated with standard anticoagulation therapies, such as blood thinning medication, a new study by researchers at the George Washington University shows that anticoagulating patients at higher doses, without traditional medical indications to do so, may be ineffective and even harmful.